Immune killing activity of lymphocytes on Hela cells expressing interleukin-12 in vitro

Abstract

The killing effects of lymphocytes on Hela cells expressing interleukin-12 (IL-12) in vitro were explored. By using gene transfection technique, full length IL-12 gene was transfected into Hela cells. The expression of IL-12 in Hela cells was detected quantitatively by ELISA; Changes in killing effects of lymphocytes on Hela cells expressing IL-12 were observed by MTT. It was found that Hela cells could express IL-12 between 24 h and 72 h after transfection. Killing activity of lymphocytes on Hela cells expressing IL-12 was significantly enhanced. It was concluded by cell transfection technique, Hela cells could express IL-12 and were more easily killed by lymphocytes.

Keywords

interleukin-12 / Hela cell / immune killing activity

References

[1] ColomboM. P., TrinchieriG.. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev, 2002, 13(2): 155-168

[2] GolabJ., ZagozdzonR.. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies. Int J Mol Med, 1999, 3(5): 537-544

[3] TangZ. Y.Modern Oncology, 20002ShanghaiPublishing House of Shanghai Medical University898-944

[4] WolfS. F., SieburthD., SypekJ.. Interleukin 12: a key modulator of immune function. Stem Cells, 1994, 12(2): 154-168

[5] BrundaM. J.. Role of IL12 as an anti-tumour agent: current status and future directions. Res Immunol, 1995, 146(7–8): 622-628

[6] SanchesR., KuiperM., Penault-llorcaF., et al.. Antitumoral effect of interleukin-12-secreting fibroblasts in a mouse model of ovarian cancer: implications for the use of ovarian cancer biopsy-derived fibroblasts as a vehicle for regional gene therapy. Cancer Gene Ther, 2000, 7(5): 707-720

[7] TasakiK., YoshidaY., MaedaT., et al.. Protective immunity is induced in murine colon carcinoma cells by the expression of interleukin-12 or interleukin-18, which activate type 1 helper T cells. Cancer Gene Ther, 2000, 7(2): 247-254

[8] NasuY., BangmaC. H., HullG. W., et al.. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther, 1999, 6(3): 338-349

[9] de GruijlT. D., BontkesH. J., van den MuysenbergA. J., et al.. Differences in cytokine mRNA profiles between premalignant and malignant lesions of the uterine cervix. Eur J Cancer, 1999, 35(3): 490-497

[10] CavalloF., SignorelliP., GiovarelliM., et al.. Antitumor efficiency of adenocarcinoma cells engineered to produce interleukin-12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst, 1997, 89(14): 1049-1058